Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
20 authors.
Naoki Ishibashi *Department of Cardiovascular Medicine Hiroshima University Graduate School of Biomedical and Health Sciences Hiroshima Japan.
Motoki Furutani *Department of Cardiovascular Medicine Hiroshima University Graduate School of Biomedical and Health Sciences Hiroshima Japan.ORCID 0000-0003-2376-900X
Mika NakashimaDepartment of Cardiovascular Medicine Hiroshima University Graduate School of Biomedical and Health Sciences Hiroshima Japan.
Shunsuke IshidaDepartment of Cardiovascular Medicine Hiroshima University Graduate School of Biomedical and Health Sciences Hiroshima Japan.
Junji MaedaDepartment of Cardiovascular Medicine Hiroshima University Graduate School of Biomedical and Health Sciences Hiroshima Japan.
Takumi SakaiDepartment of Cardiovascular Medicine Hiroshima University Graduate School of Biomedical and Health Sciences Hiroshima Japan.
Naoto OguriDepartment of Cardiovascular Medicine Hiroshima University Graduate School of Biomedical and Health Sciences Hiroshima Japan.ORCID 0000-0002-3345-4274
Shogo MiyamotoDepartment of Cardiovascular Medicine Hiroshima University Graduate School of Biomedical and Health Sciences Hiroshima Japan.ORCID 0009-0002-4294-2488
Shunsuke MiyauchiDepartment of Cardiovascular Medicine Hiroshima University Graduate School of Biomedical and Health Sciences Hiroshima Japan.ORCID 0000-0001-5781-3182
Sho OkamuraDepartment of Cardiovascular Medicine Hiroshima University Graduate School of Biomedical and Health Sciences Hiroshima Japan.ORCID 0000-0002-9512-9506
Yousaku OkuboDepartment of Cardiovascular Medicine Hiroshima University Graduate School of Biomedical and Health Sciences Hiroshima Japan.ORCID 0000-0003-4034-5356
Takehito TokuyamaDepartment of Cardiovascular Medicine Hiroshima University Graduate School of Biomedical and Health Sciences Hiroshima Japan.ORCID 0000-0003-2722-6934
Noboru OdaDepartment of Cardiovascular Medicine Hiroshima University Graduate School of Biomedical and Health Sciences Hiroshima Japan.
Takumi NishikiMedical Genome Center Research Institute, National Center for Geriatrics and Gerontology Aichi Japan.
Risa MitsumoriMedical Genome Center Research Institute, National Center for Geriatrics and Gerontology Aichi Japan.ORCID 0009-0000-3383-1327
Shumpei NiidaResearch Institute, National Center for Geriatrics and Gerontology Aichi Japan.ORCID 0000-0002-6192-8035
Kouichi OzakiDepartment of Cardiovascular Medicine Hiroshima University Graduate School of Biomedical and Health Sciences Hiroshima Japan.ORCID 0000-0003-0028-1570
Daichi ShigemizuDepartment of Cardiovascular Medicine Hiroshima University Graduate School of Biomedical and Health Sciences Hiroshima Japan.ORCID 0000-0002-4412-0552
Hideki ItohDivision of Patient Safety Hiroshima University Hospital Hiroshima Japan.ORCID 0000-0002-5104-3313
Yukiko NakanoDepartment of Cardiovascular Medicine Hiroshima University Graduate School of Biomedical and Health Sciences Hiroshima Japan.ORCID 0000-0001-5373-5164
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
backgroundBepridil is an antiarrhythmic drug used to treat paroxysmal atrial fibrillation; however, its use is limited by corrected QT interval (QTc) prolongation and the risk of ventricular arrhythmias. This study aimed to identify genetic variants associated with bepridil-associated QTc prolongation after catheter ablation for paroxysmal atrial fibrillation.
methodsA total of 523 patients who initiated bepridil therapy after catheter ablation at Hiroshima University between November 2013 and March 2023 were enrolled. Of these, 445 patients were included in a genome-wide association study, and 78 were used as an independent replication cohort. QTc was measured 1 month after treatment initiation, with QTc prolongation defined as ≥450 ms in men and ≥460 ms in women. Logistic regression analyses were conducted using additive, dominant, and recessive genetic models. Variants showing suggestive associations in the genome-wide association study (
resultsAfter quality control, 443 patients were analyzed in the genome-wide association study. Of these, 122 (28%) exhibited QTc prolongation. Under the recessive model, rs12622919, an intronic variant in the
conclusionThe
Indexed as
Anti-Arrhythmia AgentsAtrial FibrillationBepridilLong QT SyndromeAgedCatheter AblationElectrocardiographyFemaleGenome-Wide Association StudyHumansMaleMiddle AgedPharmacogenomic VariantsPolymorphism, Single NucleotideRisk FactorsAnti-Arrhythmia AgentsBepridilbepridilgenome‐wide association studyQTc prolongation
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Genetic Investigation of Corrected QT Interval Sensitivity to Oral Bepridil Hydrochloride Hydrate in Patients With Atrial Fibrillation. · full record | OpenQuestion